Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Active as of 2024-12-19 |
<Citation xmlns="http://hl7.org/fhir">
<id value="264329"/>
<meta>
<versionId value="2"/>
<lastUpdated value="2024-11-22T19:28:08.122Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Citation 264329</b></p><a name="264329"> </a><a name="hc264329"> </a><a name="264329-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 2; Last updated: 2024-11-22 19:28:08+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-journal-article-citation.html">JournalArticleCitation</a></p></div><p><b>url</b>: <a href="Citation-264329.html">Citation 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/264329, <code>https://pubmed.ncbi.nlm.nih.gov</code>/37024129, <a href="http://terminology.hl7.org/6.1.0/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt
This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid:
Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.
This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.15.11</p><p><b>version</b>: 2.0.0-ballot</p><p><b>title</b>: 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-12-19 14:29:51+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html#citation-classification-type-fevir-platform-use">Citation Classification Type fevir-platform-use</a>: FEvIR Platform Use</td><td><span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier medline-base}">Medline Base</span></td></tr></table><p><b>jurisdiction</b>: <span title="Codes:{http://unstats.un.org/unsd/methods/m49/m49.htm 001}">World</span></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>approvalDate</b>: 2023-04-10</p><p><b>lastReviewDate</b>: 2023-04-11</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/citation-classification-type citation-source}">Citation Source</span></p><p><b>classifier</b>: <span title="Codes:">MEDLINE</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/citation-classification-type medline-owner}">MEDLINE Citation Owner</span></p><p><b>classifier</b>: <span title="Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value NLM}">National Library of Medicine, Index Section</span></p></blockquote><p><b>currentState</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type medline-medline}">Medline Citation Status of Medline</span>, <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-publication-status-epublish}">PubMed PublicationStatus of epublish</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-medline}">PubMed Pubstatus of Medline</span></p><p><b>period</b>: ?? --> 2023-04-10 06:42:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-entrez}">PubMed Pubstatus of Entrez</span></p><p><b>period</b>: ?? --> 2023-04-06 20:43:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pubmed}">PubMed Pubstatus of Pubmed</span></p><p><b>period</b>: ?? --> 2023-04-07 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pmc-release}">PubMed Pubstatus of PMC release</span></p><p><b>period</b>: ?? --> 2023-04-06</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/37024129, <code>https://www.ncbi.nlm.nih.gov/pmc/</code>/PMC10077111, <code>https://doi.org</code>/10.1136/bmj-2022-074068</p><h3>Titles</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/title-type primary}">Primary title</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">English</span></td><td><div><p>Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</p>
</div></td></tr></table><h3>Abstracts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td><td><b>Copyright</b></td></tr><tr><td style="display: none">*</td><td><div><p><strong>OBJECTIVE:</strong> To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options.
<AbstractText Label="DESIGN">Systematic review and network meta-analysis.
<AbstractText Label="DATA SOURCES">Ovid Medline, Embase, and Cochrane Central up to 14 October 2022.
<AbstractText Label="ELIGIBILITY CRITERIA FOR SELECTING STUDIES">Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach.
<strong>RESULTS:</strong> The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference -8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (https://matchit.magicevidence.org/230125dist-diabetes).
<strong>CONCLUSIONS:</strong> This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes.
<AbstractText Label="SYSTEMATIC REVIEW REGISTRATION">PROSPERO CRD42022325948.</p>
</div></td><td><div><p>© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.</p>
</div></td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Gregg EW, Jakicic JM, Blackburn G, et al. Look AHEAD Research Group . Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913-21. 10.1016/S2213-8587(16)30162-0.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/27595918/">https://pubmed.ncbi.nlm.nih.gov/27595918/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/27595918</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Palmer SC, Tendal B, Mustafa RA, et al. . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. 10.1136/bmj.m4573.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/33441402/">https://pubmed.ncbi.nlm.nih.gov/33441402/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/33441402</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Li S, Vandvik PO, Lytvyn L, et al. . SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 2021;373:n1091. 10.1136/bmj.n1091.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/33975892/">https://pubmed.ncbi.nlm.nih.gov/33975892/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/33975892</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Bakris GL, Agarwal R, Anker SD, et al. FIDELIO-DKD Investigators . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-29. 10.1056/NEJMoa2025845.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/33264825/">https://pubmed.ncbi.nlm.nih.gov/33264825/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/33264825</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD Investigators . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63. 10.1056/NEJMoa2110956.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/34449181/">https://pubmed.ncbi.nlm.nih.gov/34449181/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/34449181</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Rosenstock J, Wysham C, Frías JP, et al. . Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143-55. 10.1016/S0140-6736(21)01324-6.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/34186022/">https://pubmed.ncbi.nlm.nih.gov/34186022/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/34186022</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Frías JP, Davies MJ, Rosenstock J, et al. SURPASS-2 Investigators . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-15. 10.1056/NEJMoa2107519.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/34170647/">https://pubmed.ncbi.nlm.nih.gov/34170647/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/34170647</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Ludvik B, Giorgino F, Jódar E, et al. . Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398:583-98. 10.1016/S0140-6736(21)01443-4.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/34370970/">https://pubmed.ncbi.nlm.nih.gov/34370970/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/34370970</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Del Prato S, Kahn SE, Pavo I, et al. SURPASS-4 Investigators . Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24. 10.1016/S0140-6736(21)02188-7.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/34672967/">https://pubmed.ncbi.nlm.nih.gov/34672967/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/34672967</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Dahl D, Onishi Y, Norwood P, et al. . Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA 2022;327:534-45. 10.1001/jama.2022.0078.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/35133415/">https://pubmed.ncbi.nlm.nih.gov/35133415/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/35133415</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Rydén L, Standl E. After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk. N Engl J Med 2022;387:1136-8. 10.1056/NEJMe2210531.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/36130002/">https://pubmed.ncbi.nlm.nih.gov/36130002/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/36130002</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Nathan DM, Lachin JM, Balasubramanyam A, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022;387:1063-74. 10.1056/NEJMoa2200433.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/36129996/">https://pubmed.ncbi.nlm.nih.gov/36129996/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/36129996</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Nathan DM, Lachin JM, Bebu I, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022;387:1075-88. 10.1056/NEJMoa2200436.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/36129997/">https://pubmed.ncbi.nlm.nih.gov/36129997/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/36129997</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Marx N, Ryden L, Brosius F, et al. . Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Res Clin Pract 2021;177:108870. 10.1016/j.diabres.2021.108870.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/34044026/">https://pubmed.ncbi.nlm.nih.gov/34044026/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/34044026</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. 10.1136/bmj.n71.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/33782057/">https://pubmed.ncbi.nlm.nih.gov/33782057/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/33782057</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Hutton B, Salanti G, Caldwell DM, et al. . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84. 10.7326/M14-2385.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26030634/">https://pubmed.ncbi.nlm.nih.gov/26030634/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/26030634</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Guyatt G, Busse J. Methods Commentary: Risk of Bias in Randomized Trials 1. DistillerSR. 2011. https://www.distillersr.com/resources/methodological-resources/risk-of-bias-commentary.</p>
</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Levin A, Agarwal R, Herrington WG, et al. participant authors of the International Society of Nephrology’s 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials . International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 2020;98:849-59. 10.1016/j.kint.2020.07.013.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/32998816/">https://pubmed.ncbi.nlm.nih.gov/32998816/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/32998816</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods 2012;3:312-24. 10.1002/jrsm.1058.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26053424/">https://pubmed.ncbi.nlm.nih.gov/26053424/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/26053424</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Shi Q, Wang Y, Hao Q, et al. . Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2022;399:259-69. 10.1016/S0140-6736(21)01640-8.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/34895470/">https://pubmed.ncbi.nlm.nih.gov/34895470/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/34895470</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Bhaumik DK, Amatya A, Normand S-L, et al. . Meta-Analysis of Rare Binary Adverse Event Data. J Am Stat Assoc 2012;107:555-67. 10.1080/01621459.2012.664484.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23734068/">https://pubmed.ncbi.nlm.nih.gov/23734068/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/23734068</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110. 10.1002/jrsm.1044.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/26062084/">https://pubmed.ncbi.nlm.nih.gov/26062084/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/26062084</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>König J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat Med 2013;32:5414-29. 10.1002/sim.6001.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/24123165/">https://pubmed.ncbi.nlm.nih.gov/24123165/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/24123165</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Wiksten A, Hawkins N, Piepho H-P, Gsteiger S. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. Value Health 2020;23:918-27. 10.1016/j.jval.2020.03.010.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/32762994/">https://pubmed.ncbi.nlm.nih.gov/32762994/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/32762994</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Efthimiou O, Rücker G, Schwarzer G, Higgins JPT, Egger M, Salanti G. Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 2019;38:2992-3012. 10.1002/sim.8158.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/30997687/">https://pubmed.ncbi.nlm.nih.gov/30997687/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/30997687</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Schandelmaier S, Briel M, Varadhan R, et al. . Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020;192:E901-6. 10.1503/cmaj.200077.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/32778601/">https://pubmed.ncbi.nlm.nih.gov/32778601/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/32778601</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Balshem H, Helfand M, Schünemann HJ, et al. . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. 10.1016/j.jclinepi.2010.07.015.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/21208779/">https://pubmed.ncbi.nlm.nih.gov/21208779/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/21208779</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Davies AL, Papakonstantinou T, Nikolakopoulou A, Rücker G, Galla T. Network meta-analysis and random walks. Stat Med 2022;41:2091-114. 10.1002/sim.9346.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/35293631/">https://pubmed.ncbi.nlm.nih.gov/35293631/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/35293631</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Puhan MA, Schünemann HJ, Murad MH, et al. GRADE Working Group . A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25252733/">https://pubmed.ncbi.nlm.nih.gov/25252733/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/25252733</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 2021;137:163-75. 10.1016/j.jclinepi.2021.03.026.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/33857619/">https://pubmed.ncbi.nlm.nih.gov/33857619/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/33857619</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol 2022;150:216-24. 10.1016/j.jclinepi.2022.07.014</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/35934265/">https://pubmed.ncbi.nlm.nih.gov/35934265/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/35934265</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE working group . GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020;371:m3900. 10.1136/bmj.m3900.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/33177059/">https://pubmed.ncbi.nlm.nih.gov/33177059/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/33177059</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Phillips MR, Sadeghirad B, Busse JW, et al. . Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. BMJ Open 2022;12:e056400. 10.1136/bmjopen-2021-056400.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/35688599/">https://pubmed.ncbi.nlm.nih.gov/35688599/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/35688599</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Buchan TA, Malik A, Chan C, et al. . Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. Heart 2021;107:1962-73. 10.1136/heartjnl-2021-319243.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/33833070/">https://pubmed.ncbi.nlm.nih.gov/33833070/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/33833070</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Wright AK, Carr MJ, Kontopantelis E, et al. . Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care 2022;45:909-18. 10.2337/dc21-1113.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/35100355/">https://pubmed.ncbi.nlm.nih.gov/35100355/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/35100355</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Rossing P, Anker SD, Filippatos G, et al. FIDELIO-DKD and FIGARO-DKD Investigators . Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care 2022;45:2991-8. 10.2337/dc22-0294.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/35972218/">https://pubmed.ncbi.nlm.nih.gov/35972218/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/35972218</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Sato N, Ajioka M, Yamada T, et al. ARTS-HF Japan study group . A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J 2016;80:1113-22. 10.1253/circj.CJ-16-0122.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/27074824/">https://pubmed.ncbi.nlm.nih.gov/27074824/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/27074824</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Ruilope LM, Pitt B, Anker SD, et al. . Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant 2023;38:372-83.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/35451488/">https://pubmed.ncbi.nlm.nih.gov/35451488/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/35451488</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Bayer. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%). Clinicaltrials.gov. 2022. https://clinicaltrials.gov/ct2/show/NCT04435626.</p>
</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. Pharmacol Res 2021;172:105835. 10.1016/j.phrs.2021.105835.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/34438065/">https://pubmed.ncbi.nlm.nih.gov/34438065/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/34438065</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: </p><div><p>Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT). clinicaltrials.gov 2022. https://clinicaltrials.gov/ct2/show/NCT04255433.</p>
</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:642-53. 10.1038/s41574-020-0399-8.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/32929230/">https://pubmed.ncbi.nlm.nih.gov/32929230/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/32929230</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Liu J, Li L, Li S, et al. . Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22:1619-27. 10.1111/dom.14075.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/32364674/">https://pubmed.ncbi.nlm.nih.gov/32364674/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/32364674</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>citation</b>: </p><div><p>Lin C, Zhu X, Cai X, et al. . SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol 2021;20:91. 10.1186/s12933-021-01276-9.</p>
</div><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/33910574/">https://pubmed.ncbi.nlm.nih.gov/33910574/</a></td></tr></table><p><b>resourceReference</b>: Identifier: <code>https://pubmed.ncbi.nlm.nih.gov</code>/33910574</p></blockquote><blockquote><p><b>publicationForm</b></p><blockquote><p><b>publishedIn</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/published-in-type D020492}">Periodical</span></p><p><b>identifier</b>: Electronic ISSN Type/1756-1833, ISOAbbreviation/BMJ, ISSN Linking/0959-8138, Medline Title Abbreviation/BMJ, NLM Unique ID/8900488</p><p><b>title</b>: BMJ (Clinical research ed.)</p><p><b>publisherLocation</b>: England</p></blockquote><p><b>citedMedium</b>: <span title="Codes:{http://hl7.org/fhir/cited-medium internet}">Internet</span></p><p><b>volume</b>: 381</p><p><b>articleDate</b>: 2023-04-06</p><p><b>publicationDateText</b>: 2023-Apr-06</p><p><b>language</b>: <span title="Codes:{urn:ietf:bcp:47 en}">English</span></p><p><b>pageString</b>: e074068</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: <span title="Codes:{http://hl7.org/fhir/cited-medium internet-without-issue}">Internet without issue</span></p><p><b>articleDate</b>: 2023-04-06</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/artifact-url-classifier abstract}">Abstract</span></p><p><b>url</b>: <a href="https://pubmed.ncbi.nlm.nih.gov/37024129/">https://pubmed.ncbi.nlm.nih.gov/37024129/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/artifact-url-classifier doi-based}">DOI Based</span></p><p><b>url</b>: <a href="https://doi.org/10.1136/bmj-2022-074068">https://doi.org/10.1136/bmj-2022-074068</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type publishing-model}">Publishing Model</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier Electronic}">Electronic</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type chemical}">Chemical</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000077203}">Sodium-Glucose Transporter 2 Inhibitors</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D000451}">Mineralocorticoid Receptor Antagonists</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D000067757}">Glucagon-Like Peptide-1 Receptor</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">MeSH heading</span></p><p><b>artifactAssessment</b>: <a href="#hc264329/meshHeading0">ArtifactAssessment: artifact[x] = this resource</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type publication-type}">Publication type</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D017418}">Meta-Analysis</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D000078182}">Systematic Review</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D016428}">Journal Article</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type knowledge-artifact-type}">Knowledge Artifact Type</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>artifactAssessment</b>: Classifier added by Computable Publishing LLC</p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type citation-subset}">Citation subset</span></p><p><b>classifier</b>: <span title="Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset IM}">IM</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor0">Shi Q</a></p><p><b>forenameInitials</b>: Q</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor1">Nong K</a></p><p><b>forenameInitials</b>: K</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor2">Vandvik PO</a></p><p><b>forenameInitials</b>: PO</p><p><b>affiliation</b>: Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor3">Guyatt GH</a></p><p><b>forenameInitials</b>: GH</p><p><b>affiliation</b>: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor4">Schnell O</a></p><p><b>forenameInitials</b>: O</p><p><b>affiliation</b>: Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor5">Rydén L</a></p><p><b>forenameInitials</b>: L</p><p><b>affiliation</b>: Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor6">Marx N</a></p><p><b>forenameInitials</b>: N</p><p><b>affiliation</b>: Clinic for Cardiology, Angiology, and Intensive Care Medicine, RWTH Aachen University, University Hospital Aachen, Aachen, Germany.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor7">Brosius FC</a></p><p><b>forenameInitials</b>: FC</p><p><b>affiliation</b>: Division of Nephrology, University of Arizona College of Medicine Tucson, Tucson, AZ, USA.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor8">Mustafa RA</a></p><p><b>forenameInitials</b>: RA</p><p><b>affiliation</b>: Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Kansas City, MI, USA.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor9">Agarwal A</a></p><p><b>forenameInitials</b>: A</p><p><b>affiliation</b>: </p><ul><li>Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.</li><li>Department of Medicine, McMaster University, Hamilton, ON, Canada.</li></ul></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor10">Zou X</a></p><p><b>forenameInitials</b>: X</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor11">Mao Y</a></p><p><b>forenameInitials</b>: Y</p><p><b>affiliation</b>: Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor12">Asadollahifar A</a></p><p><b>forenameInitials</b>: A</p><p><b>affiliation</b>: Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor13">Chowdhury SR</a></p><p><b>forenameInitials</b>: SR</p><p><b>affiliation</b>: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor14">Zhai C</a></p><p><b>forenameInitials</b>: C</p><p><b>affiliation</b>: Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor15">Gupta S</a></p><p><b>forenameInitials</b>: S</p><p><b>affiliation</b>: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor16">Gao Y</a></p><p><b>forenameInitials</b>: Y</p><p><b>affiliation</b>: </p><ul><li>Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.</li><li>Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.</li></ul></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor17">Lima JP</a></p><p><b>forenameInitials</b>: JP</p><p><b>affiliation</b>: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor18">Numata K</a></p><p><b>forenameInitials</b>: K</p><p><b>affiliation</b>: Department of Emergency Medicine, St Marianna University School of Medicine, Kawasaki, Japan.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor19">Qiao Z</a></p><p><b>forenameInitials</b>: Z</p><p><b>affiliation</b>: West China School of Medicine, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor20">Fan Q</a></p><p><b>forenameInitials</b>: Q</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor21">Yang Q</a></p><p><b>forenameInitials</b>: Q</p><p><b>affiliation</b>: Department of Nephrology, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor22">Jin Y</a></p><p><b>forenameInitials</b>: Y</p><p><b>affiliation</b>: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor23">Ge L</a></p><p><b>forenameInitials</b>: L</p><p><b>affiliation</b>: Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor24">Yang Q</a></p><p><b>forenameInitials</b>: Q</p><p><b>affiliation</b>: Evidence-Based Nursing Centre, School of Nursing, Lanzhou University, Lanzhou, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor25">Zhu H</a></p><p><b>forenameInitials</b>: H</p><p><b>affiliation</b>: Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor26">Yang F</a></p><p><b>forenameInitials</b>: F</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Chengdu Fifth People's Hospital, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor27">Chen Z</a></p><p><b>forenameInitials</b>: Z</p><p><b>affiliation</b>: Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Tianjin, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor28">Lu X</a></p><p><b>forenameInitials</b>: X</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor29">He S</a></p><p><b>forenameInitials</b>: S</p><p><b>affiliation</b>: Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor30">Chen X</a></p><p><b>forenameInitials</b>: X</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, First People's Hospital of Shuangliu District, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor31">Lyu X</a></p><p><b>forenameInitials</b>: X</p><p><b>affiliation</b>: Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor32">An X</a></p><p><b>forenameInitials</b>: X</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor33">Chen Y</a></p><p><b>forenameInitials</b>: Y</p><p><b>affiliation</b>: Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor34">Hao Q</a></p><p><b>forenameInitials</b>: Q</p><p><b>affiliation</b>: School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor35">Standl E</a></p><p><b>forenameInitials</b>: E</p><p><b>affiliation</b>: Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor36">Siemieniuk R</a></p><p><b>forenameInitials</b>: R</p><p><b>affiliation</b>: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor37">Agoritsas T</a></p><p><b>forenameInitials</b>: T</p><p><b>affiliation</b>: </p><ul><li>Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.</li><li>Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland.</li></ul></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor38">Tian H</a></p><p><b>forenameInitials</b>: H</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc264329/contributor39">Li S</a></p><p><b>forenameInitials</b>: S</p><p><b>affiliation</b>: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China lisheyu@gmail.com.</p></blockquote></blockquote></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor0</b></p><a name="264329/contributor0"> </a><a name="hc264329/contributor0"> </a><a name="264329/contributor0-en-US"> </a><p><b>identifier</b>: ORCID/0000-0003-4299-5889</p><p><b>name</b>: Qingyang Shi </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor1</b></p><a name="264329/contributor1"> </a><a name="hc264329/contributor1"> </a><a name="264329/contributor1-en-US"> </a><p><b>name</b>: Kailei Nong </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor2</b></p><a name="264329/contributor2"> </a><a name="hc264329/contributor2"> </a><a name="264329/contributor2-en-US"> </a><p><b>name</b>: Per Olav Vandvik </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor3</b></p><a name="264329/contributor3"> </a><a name="hc264329/contributor3"> </a><a name="264329/contributor3-en-US"> </a><p><b>name</b>: Gordon H Guyatt </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor4</b></p><a name="264329/contributor4"> </a><a name="hc264329/contributor4"> </a><a name="264329/contributor4-en-US"> </a><p><b>name</b>: Oliver Schnell </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor5</b></p><a name="264329/contributor5"> </a><a name="hc264329/contributor5"> </a><a name="264329/contributor5-en-US"> </a><p><b>name</b>: Lars Rydén </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor6</b></p><a name="264329/contributor6"> </a><a name="hc264329/contributor6"> </a><a name="264329/contributor6-en-US"> </a><p><b>name</b>: Nikolaus Marx </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor7</b></p><a name="264329/contributor7"> </a><a name="hc264329/contributor7"> </a><a name="264329/contributor7-en-US"> </a><p><b>name</b>: Frank C Brosius </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor8</b></p><a name="264329/contributor8"> </a><a name="hc264329/contributor8"> </a><a name="264329/contributor8-en-US"> </a><p><b>name</b>: Reem A Mustafa </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor9</b></p><a name="264329/contributor9"> </a><a name="hc264329/contributor9"> </a><a name="264329/contributor9-en-US"> </a><p><b>name</b>: Arnav Agarwal </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor10</b></p><a name="264329/contributor10"> </a><a name="hc264329/contributor10"> </a><a name="264329/contributor10-en-US"> </a><p><b>name</b>: Xinyu Zou </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor11</b></p><a name="264329/contributor11"> </a><a name="hc264329/contributor11"> </a><a name="264329/contributor11-en-US"> </a><p><b>name</b>: Yunhe Mao </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor12</b></p><a name="264329/contributor12"> </a><a name="hc264329/contributor12"> </a><a name="264329/contributor12-en-US"> </a><p><b>name</b>: Aminreza Asadollahifar </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor13</b></p><a name="264329/contributor13"> </a><a name="hc264329/contributor13"> </a><a name="264329/contributor13-en-US"> </a><p><b>name</b>: Saifur Rahman Chowdhury </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor14</b></p><a name="264329/contributor14"> </a><a name="hc264329/contributor14"> </a><a name="264329/contributor14-en-US"> </a><p><b>name</b>: Chunjuan Zhai </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor15</b></p><a name="264329/contributor15"> </a><a name="hc264329/contributor15"> </a><a name="264329/contributor15-en-US"> </a><p><b>name</b>: Sana Gupta </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor16</b></p><a name="264329/contributor16"> </a><a name="hc264329/contributor16"> </a><a name="264329/contributor16-en-US"> </a><p><b>name</b>: Ya Gao </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor17</b></p><a name="264329/contributor17"> </a><a name="hc264329/contributor17"> </a><a name="264329/contributor17-en-US"> </a><p><b>name</b>: João Pedro Lima </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor18</b></p><a name="264329/contributor18"> </a><a name="hc264329/contributor18"> </a><a name="264329/contributor18-en-US"> </a><p><b>name</b>: Kenji Numata </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor19</b></p><a name="264329/contributor19"> </a><a name="hc264329/contributor19"> </a><a name="264329/contributor19-en-US"> </a><p><b>name</b>: Zhi Qiao </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor20</b></p><a name="264329/contributor20"> </a><a name="hc264329/contributor20"> </a><a name="264329/contributor20-en-US"> </a><p><b>name</b>: Qinlin Fan </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor21</b></p><a name="264329/contributor21"> </a><a name="hc264329/contributor21"> </a><a name="264329/contributor21-en-US"> </a><p><b>name</b>: Qinbo Yang </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor22</b></p><a name="264329/contributor22"> </a><a name="hc264329/contributor22"> </a><a name="264329/contributor22-en-US"> </a><p><b>name</b>: Yinghui Jin </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor23</b></p><a name="264329/contributor23"> </a><a name="hc264329/contributor23"> </a><a name="264329/contributor23-en-US"> </a><p><b>name</b>: Long Ge </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor24</b></p><a name="264329/contributor24"> </a><a name="hc264329/contributor24"> </a><a name="264329/contributor24-en-US"> </a><p><b>name</b>: Qiuyu Yang </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor25</b></p><a name="264329/contributor25"> </a><a name="hc264329/contributor25"> </a><a name="264329/contributor25-en-US"> </a><p><b>name</b>: Hongfei Zhu </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor26</b></p><a name="264329/contributor26"> </a><a name="hc264329/contributor26"> </a><a name="264329/contributor26-en-US"> </a><p><b>name</b>: Fan Yang </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor27</b></p><a name="264329/contributor27"> </a><a name="hc264329/contributor27"> </a><a name="264329/contributor27-en-US"> </a><p><b>name</b>: Zhe Chen </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor28</b></p><a name="264329/contributor28"> </a><a name="hc264329/contributor28"> </a><a name="264329/contributor28-en-US"> </a><p><b>name</b>: Xi Lu </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor29</b></p><a name="264329/contributor29"> </a><a name="hc264329/contributor29"> </a><a name="264329/contributor29-en-US"> </a><p><b>name</b>: Siyu He </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor30</b></p><a name="264329/contributor30"> </a><a name="hc264329/contributor30"> </a><a name="264329/contributor30-en-US"> </a><p><b>name</b>: Xiangyang Chen </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor31</b></p><a name="264329/contributor31"> </a><a name="hc264329/contributor31"> </a><a name="264329/contributor31-en-US"> </a><p><b>name</b>: Xiafei Lyu </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor32</b></p><a name="264329/contributor32"> </a><a name="hc264329/contributor32"> </a><a name="264329/contributor32-en-US"> </a><p><b>name</b>: Xingxing An </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor33</b></p><a name="264329/contributor33"> </a><a name="hc264329/contributor33"> </a><a name="264329/contributor33-en-US"> </a><p><b>name</b>: Yaolong Chen </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor34</b></p><a name="264329/contributor34"> </a><a name="hc264329/contributor34"> </a><a name="264329/contributor34-en-US"> </a><p><b>name</b>: Qiukui Hao </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor35</b></p><a name="264329/contributor35"> </a><a name="hc264329/contributor35"> </a><a name="264329/contributor35-en-US"> </a><p><b>name</b>: Eberhard Standl </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor36</b></p><a name="264329/contributor36"> </a><a name="hc264329/contributor36"> </a><a name="264329/contributor36-en-US"> </a><p><b>name</b>: Reed Siemieniuk </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor37</b></p><a name="264329/contributor37"> </a><a name="hc264329/contributor37"> </a><a name="264329/contributor37-en-US"> </a><p><b>name</b>: Thomas Agoritsas </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor38</b></p><a name="264329/contributor38"> </a><a name="hc264329/contributor38"> </a><a name="264329/contributor38-en-US"> </a><p><b>name</b>: Haoming Tian </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor39</b></p><a name="264329/contributor39"> </a><a name="hc264329/contributor39"> </a><a name="264329/contributor39-en-US"> </a><p><b>identifier</b>: ORCID/0000-0003-0060-0287</p><p><b>name</b>: Sheyu Li </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ArtifactAssessment #meshHeading0</b></p><a name="264329/meshHeading0"> </a><a name="hc264329/meshHeading0"> </a><a name="264329/meshHeading0-en-US"> </a><p><b>artifact</b>: <a href="#hc264329">Citation 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</a></p><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000328}">Adult</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D006801}">Humans</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D003924}">Diabetes Mellitus, Type 2</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is Major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000188}">drug therapy</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000077203}">Sodium-Glucose Transporter 2 Inhibitors</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is Major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000009}">adverse effects</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000451}">Mineralocorticoid Receptor Antagonists</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000009}">adverse effects</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000071076}">Network Meta-Analysis</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000067757}">Glucagon-Like Peptide-1 Receptor</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000627}">therapeutic use</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D011788}">Quality of Life</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D007676}">Kidney Failure, Chronic</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is Major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D006333}">Heart Failure</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is Major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000188}">drug therapy</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49487}">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D016032}">Randomized Controlled Trials as Topic</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote></blockquote></div>
</text>
<contained>
<Practitioner>
<id value="contributor0"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="PRN"/>
<display value="Provider number"/>
</coding>
<text value="ORCID"/>
</type>
<system value="https://orcid.org/"/>
<value value="0000-0003-4299-5889"/>
</identifier>
<name>
<family value="Shi"/>
<given value="Qingyang"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor1"/>
<name>
<family value="Nong"/>
<given value="Kailei"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor2"/>
<name>
<family value="Vandvik"/>
<given value="Per Olav"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor3"/>
<name>
<family value="Guyatt"/>
<given value="Gordon H"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor4"/>
<name>
<family value="Schnell"/>
<given value="Oliver"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor5"/>
<name>
<family value="Rydén"/>
<given value="Lars"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor6"/>
<name>
<family value="Marx"/>
<given value="Nikolaus"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor7"/>
<name>
<family value="Brosius"/>
<given value="Frank C"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor8"/>
<name>
<family value="Mustafa"/>
<given value="Reem A"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor9"/>
<name>
<family value="Agarwal"/>
<given value="Arnav"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor10"/>
<name>
<family value="Zou"/>
<given value="Xinyu"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor11"/>
<name>
<family value="Mao"/>
<given value="Yunhe"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor12"/>
<name>
<family value="Asadollahifar"/>
<given value="Aminreza"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor13"/>
<name>
<family value="Chowdhury"/>
<given value="Saifur Rahman"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor14"/>
<name>
<family value="Zhai"/>
<given value="Chunjuan"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor15"/>
<name>
<family value="Gupta"/>
<given value="Sana"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor16"/>
<name>
<family value="Gao"/>
<given value="Ya"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor17"/>
<name>
<family value="Lima"/>
<given value="João Pedro"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor18"/>
<name>
<family value="Numata"/>
<given value="Kenji"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor19"/>
<name>
<family value="Qiao"/>
<given value="Zhi"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor20"/>
<name>
<family value="Fan"/>
<given value="Qinlin"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor21"/>
<name>
<family value="Yang"/>
<given value="Qinbo"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor22"/>
<name>
<family value="Jin"/>
<given value="Yinghui"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor23"/>
<name>
<family value="Ge"/>
<given value="Long"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor24"/>
<name>
<family value="Yang"/>
<given value="Qiuyu"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor25"/>
<name>
<family value="Zhu"/>
<given value="Hongfei"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor26"/>
<name>
<family value="Yang"/>
<given value="Fan"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor27"/>
<name>
<family value="Chen"/>
<given value="Zhe"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor28"/>
<name>
<family value="Lu"/>
<given value="Xi"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor29"/>
<name>
<family value="He"/>
<given value="Siyu"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor30"/>
<name>
<family value="Chen"/>
<given value="Xiangyang"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor31"/>
<name>
<family value="Lyu"/>
<given value="Xiafei"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor32"/>
<name>
<family value="An"/>
<given value="Xingxing"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor33"/>
<name>
<family value="Chen"/>
<given value="Yaolong"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor34"/>
<name>
<family value="Hao"/>
<given value="Qiukui"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor35"/>
<name>
<family value="Standl"/>
<given value="Eberhard"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor36"/>
<name>
<family value="Siemieniuk"/>
<given value="Reed"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor37"/>
<name>
<family value="Agoritsas"/>
<given value="Thomas"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor38"/>
<name>
<family value="Tian"/>
<given value="Haoming"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor39"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="PRN"/>
<display value="Provider number"/>
</coding>
<text value="ORCID"/>
</type>
<system value="https://orcid.org/"/>
<value value="0000-0003-0060-0287"/>
</identifier>
<name>
<family value="Li"/>
<given value="Sheyu"/>
</name>
</Practitioner>
</contained>
<contained>
<ArtifactAssessment>
<id value="meshHeading0"/>
<artifactReference>
<reference value="#"/>
<type value="Citation"/>
</artifactReference>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000328"/>
<display value="Adult"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D006801"/>
<display value="Humans"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D003924"/>
<display value="Diabetes Mellitus, Type 2"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is Major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000188"/>
<display value="drug therapy"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000077203"/>
<display value="Sodium-Glucose Transporter 2 Inhibitors"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is Major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000009"/>
<display value="adverse effects"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000451"/>
<display value="Mineralocorticoid Receptor Antagonists"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000009"/>
<display value="adverse effects"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000071076"/>
<display value="Network Meta-Analysis"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000067757"/>
<display value="Glucagon-Like Peptide-1 Receptor"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000627"/>
<display value="therapeutic use"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D011788"/>
<display value="Quality of Life"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D007676"/>
<display value="Kidney Failure, Chronic"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is Major topic"/>
</classifier>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D006333"/>
<display value="Heart Failure"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is Major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000188"/>
<display value="drug therapy"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016032"/>
<display value="Randomized Controlled Trials as Topic"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
</ArtifactAssessment>
</contained>
<url value="https://fevir.net/resources/Citation/264329"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="urn:ietf:rfc:3986"/>
<value value="https://fevir.net/FOI/264329"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="37024129"/>
</identifier>
<identifier>
<system value="urn:ietf:rfc:3986"/>
<value value="urn:oid:2.16.840.1.113883.4.642.40.44.15.11"/>
</identifier>
<version value="2.0.0-ballot"/>
<title
value="37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials."/>
<status value="active"/>
<date value="2024-12-19T14:29:51+00:00"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description
value="This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
<useContext>
<code>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="fevir-platform-use"/>
<display value="FEvIR Platform Use"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="medline-base"/>
<display value="Medline Base"/>
<userSelected value="false"/>
</coding>
</valueCodeableConcept>
</useContext>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
<display value="World"/>
</coding>
</jurisdiction>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<approvalDate value="2023-04-10"/>
<lastReviewDate value="2023-04-11"/>
<author>
<name value="Computable Publishing®: MEDLINE-to-FEvIR Converter"/>
</author>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="citation-source"/>
<display value="Citation Source"/>
</coding>
</type>
<classifier>
<text value="MEDLINE"/>
</classifier>
</classification>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="medline-owner"/>
<display value="MEDLINE Citation Owner"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"/>
<code value="NLM"/>
<display value="National Library of Medicine, Index Section"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="medline-medline"/>
<display value="Medline Citation Status of Medline"/>
</coding>
</currentState>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-publication-status-epublish"/>
<display value="PubMed PublicationStatus of epublish"/>
</coding>
</currentState>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-medline"/>
<display value="PubMed Pubstatus of Medline"/>
</coding>
</activity>
<period>
<end value="2023-04-10T06:42:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-entrez"/>
<display value="PubMed Pubstatus of Entrez"/>
</coding>
</activity>
<period>
<end value="2023-04-06T20:43:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-pubmed"/>
<display value="PubMed Pubstatus of Pubmed"/>
</coding>
</activity>
<period>
<end value="2023-04-07T06:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-pmc-release"/>
<display value="PubMed Pubstatus of PMC release"/>
</coding>
</activity>
<period>
<end value="2023-04-06"/>
</period>
</statusDate>
<citedArtifact>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="37024129"/>
</identifier>
<identifier>
<system value="https://www.ncbi.nlm.nih.gov/pmc/"/>
<value value="PMC10077111"/>
</identifier>
<identifier>
<system value="https://doi.org"/>
<value value="10.1136/bmj-2022-074068"/>
</identifier>
<title>
<type>
<coding>
<system value="http://hl7.org/fhir/title-type"/>
<code value="primary"/>
<display value="Primary title"/>
</coding>
</type>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<text
value="Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials."/>
</title>
<abstract>
<text
value="**OBJECTIVE:** To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options.
<AbstractText Label="DESIGN">Systematic review and network meta-analysis.
<AbstractText Label="DATA SOURCES">Ovid Medline, Embase, and Cochrane Central up to 14 October 2022.
<AbstractText Label="ELIGIBILITY CRITERIA FOR SELECTING STUDIES">Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach.
**RESULTS:** The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference -8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (https://matchit.magicevidence.org/230125dist-diabetes).
**CONCLUSIONS:** This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes.
<AbstractText Label="SYSTEMATIC REVIEW REGISTRATION">PROSPERO CRD42022325948."/>
<copyright
value="© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ."/>
</abstract>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Gregg EW, Jakicic JM, Blackburn G, et al. Look AHEAD Research Group . Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913-21. 10.1016/S2213-8587(16)30162-0."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/27595918/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="27595918"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Palmer SC, Tendal B, Mustafa RA, et al. . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. 10.1136/bmj.m4573."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/33441402/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="33441402"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Li S, Vandvik PO, Lytvyn L, et al. . SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 2021;373:n1091. 10.1136/bmj.n1091."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/33975892/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="33975892"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Bakris GL, Agarwal R, Anker SD, et al. FIDELIO-DKD Investigators . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-29. 10.1056/NEJMoa2025845."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/33264825/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="33264825"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD Investigators . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63. 10.1056/NEJMoa2110956."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/34449181/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="34449181"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Rosenstock J, Wysham C, Frías JP, et al. . Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143-55. 10.1016/S0140-6736(21)01324-6."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/34186022/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="34186022"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Frías JP, Davies MJ, Rosenstock J, et al. SURPASS-2 Investigators . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-15. 10.1056/NEJMoa2107519."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/34170647/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="34170647"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Ludvik B, Giorgino F, Jódar E, et al. . Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398:583-98. 10.1016/S0140-6736(21)01443-4."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/34370970/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="34370970"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Del Prato S, Kahn SE, Pavo I, et al. SURPASS-4 Investigators . Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24. 10.1016/S0140-6736(21)02188-7."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/34672967/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="34672967"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Dahl D, Onishi Y, Norwood P, et al. . Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA 2022;327:534-45. 10.1001/jama.2022.0078."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/35133415/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="35133415"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Rydén L, Standl E. After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk. N Engl J Med 2022;387:1136-8. 10.1056/NEJMe2210531."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/36130002/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="36130002"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Nathan DM, Lachin JM, Balasubramanyam A, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022;387:1063-74. 10.1056/NEJMoa2200433."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/36129996/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="36129996"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Nathan DM, Lachin JM, Bebu I, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022;387:1075-88. 10.1056/NEJMoa2200436."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/36129997/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="36129997"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Marx N, Ryden L, Brosius F, et al. . Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Res Clin Pract 2021;177:108870. 10.1016/j.diabres.2021.108870."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/34044026/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="34044026"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. 10.1136/bmj.n71."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/33782057/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="33782057"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Hutton B, Salanti G, Caldwell DM, et al. . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84. 10.7326/M14-2385."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/26030634/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="26030634"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Guyatt G, Busse J. Methods Commentary: Risk of Bias in Randomized Trials 1. DistillerSR. 2011. https://www.distillersr.com/resources/methodological-resources/risk-of-bias-commentary."/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Levin A, Agarwal R, Herrington WG, et al. participant authors of the International Society of Nephrology’s 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials . International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 2020;98:849-59. 10.1016/j.kint.2020.07.013."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/32998816/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="32998816"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods 2012;3:312-24. 10.1002/jrsm.1058."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/26053424/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="26053424"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Shi Q, Wang Y, Hao Q, et al. . Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2022;399:259-69. 10.1016/S0140-6736(21)01640-8."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/34895470/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="34895470"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Bhaumik DK, Amatya A, Normand S-L, et al. . Meta-Analysis of Rare Binary Adverse Event Data. J Am Stat Assoc 2012;107:555-67. 10.1080/01621459.2012.664484."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/23734068/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="23734068"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110. 10.1002/jrsm.1044."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/26062084/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="26062084"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="König J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat Med 2013;32:5414-29. 10.1002/sim.6001."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/24123165/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="24123165"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Wiksten A, Hawkins N, Piepho H-P, Gsteiger S. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. Value Health 2020;23:918-27. 10.1016/j.jval.2020.03.010."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/32762994/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="32762994"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Efthimiou O, Rücker G, Schwarzer G, Higgins JPT, Egger M, Salanti G. Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 2019;38:2992-3012. 10.1002/sim.8158."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/30997687/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="30997687"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Schandelmaier S, Briel M, Varadhan R, et al. . Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020;192:E901-6. 10.1503/cmaj.200077."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/32778601/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="32778601"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Balshem H, Helfand M, Schünemann HJ, et al. . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. 10.1016/j.jclinepi.2010.07.015."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/21208779/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="21208779"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Davies AL, Papakonstantinou T, Nikolakopoulou A, Rücker G, Galla T. Network meta-analysis and random walks. Stat Med 2022;41:2091-114. 10.1002/sim.9346."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/35293631/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="35293631"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Puhan MA, Schünemann HJ, Murad MH, et al. GRADE Working Group . A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/25252733/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="25252733"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 2021;137:163-75. 10.1016/j.jclinepi.2021.03.026."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/33857619/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="33857619"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol 2022;150:216-24. 10.1016/j.jclinepi.2022.07.014"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/35934265/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="35934265"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE working group . GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020;371:m3900. 10.1136/bmj.m3900."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/33177059/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="33177059"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Phillips MR, Sadeghirad B, Busse JW, et al. . Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. BMJ Open 2022;12:e056400. 10.1136/bmjopen-2021-056400."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/35688599/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="35688599"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Buchan TA, Malik A, Chan C, et al. . Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. Heart 2021;107:1962-73. 10.1136/heartjnl-2021-319243."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/33833070/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="33833070"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Wright AK, Carr MJ, Kontopantelis E, et al. . Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care 2022;45:909-18. 10.2337/dc21-1113."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/35100355/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="35100355"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Rossing P, Anker SD, Filippatos G, et al. FIDELIO-DKD and FIGARO-DKD Investigators . Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care 2022;45:2991-8. 10.2337/dc22-0294."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/35972218/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="35972218"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Sato N, Ajioka M, Yamada T, et al. ARTS-HF Japan study group . A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J 2016;80:1113-22. 10.1253/circj.CJ-16-0122."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/27074824/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="27074824"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Ruilope LM, Pitt B, Anker SD, et al. . Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant 2023;38:372-83."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/35451488/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="35451488"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Bayer. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%). Clinicaltrials.gov. 2022. https://clinicaltrials.gov/ct2/show/NCT04435626."/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. Pharmacol Res 2021;172:105835. 10.1016/j.phrs.2021.105835."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/34438065/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="34438065"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT). clinicaltrials.gov 2022. https://clinicaltrials.gov/ct2/show/NCT04255433."/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:642-53. 10.1038/s41574-020-0399-8."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/32929230/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="32929230"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Liu J, Li L, Li S, et al. . Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22:1619-27. 10.1111/dom.14075."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/32364674/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="32364674"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Lin C, Zhu X, Cai X, et al. . SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol 2021;20:91. 10.1186/s12933-021-01276-9."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/33910574/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="33910574"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<publicationForm>
<publishedIn>
<type>
<coding>
<system value="http://hl7.org/fhir/published-in-type"/>
<code value="D020492"/>
<display value="Periodical"/>
</coding>
</type>
<identifier>
<type>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn"/>
<code value="Electronic"/>
<display value="Electronic"/>
</coding>
<text value="Electronic ISSN Type"/>
</type>
<system value="https://portal.issn.org"/>
<value value="1756-1833"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISOAbbreviation"/>
</type>
<system
value="https://www.issn.org/services/online-services/access-to-the-ltwa/"/>
<value value="BMJ"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISSN Linking"/>
</type>
<system
value="https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"/>
<value value="0959-8138"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="Medline Title Abbreviation"/>
</type>
<system
value="https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"/>
<value value="BMJ"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="NLM Unique ID"/>
</type>
<system
value="https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"/>
<value value="8900488"/>
</identifier>
<title value="BMJ (Clinical research ed.)"/>
<publisherLocation value="England"/>
</publishedIn>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="internet"/>
<display value="Internet"/>
</coding>
</citedMedium>
<volume value="381"/>
<articleDate value="2023-04-06"/>
<publicationDateText value="2023-Apr-06"/>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<pageString value="e074068"/>
</publicationForm>
<publicationForm>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="internet-without-issue"/>
<display value="Internet without issue"/>
</coding>
</citedMedium>
<articleDate value="2023-04-06"/>
</publicationForm>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="abstract"/>
<display value="Abstract"/>
</coding>
</classifier>
<url value="https://pubmed.ncbi.nlm.nih.gov/37024129/"/>
</webLocation>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="doi-based"/>
<display value="DOI Based"/>
</coding>
</classifier>
<url value="https://doi.org/10.1136/bmj-2022-074068"/>
</webLocation>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publishing-model"/>
<display value="Publishing Model"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="Electronic"/>
<display value="Electronic"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="chemical"/>
<display value="Chemical"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000077203"/>
<display value="Sodium-Glucose Transporter 2 Inhibitors"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000451"/>
<display value="Mineralocorticoid Receptor Antagonists"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000067757"/>
<display value="Glucagon-Like Peptide-1 Receptor"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
</type>
<artifactAssessment>
<reference value="#meshHeading0"/>
<type value="ArtifactAssessment"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publication-type"/>
<display value="Publication type"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D017418"/>
<display value="Meta-Analysis"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000078182"/>
<display value="Systematic Review"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="knowledge-artifact-type"/>
<display value="Knowledge Artifact Type"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
<artifactAssessment>
<display value="Classifier added by Computable Publishing LLC"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="citation-subset"/>
<display value="Citation subset"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset"/>
<code value="IM"/>
<display value="IM"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<contributorship>
<complete value="true"/>
<entry>
<contributor>
<reference value="#contributor0"/>
<type value="Practitioner"/>
<display value="Shi Q"/>
</contributor>
<forenameInitials value="Q"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor1"/>
<type value="Practitioner"/>
<display value="Nong K"/>
</contributor>
<forenameInitials value="K"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor2"/>
<type value="Practitioner"/>
<display value="Vandvik PO"/>
</contributor>
<forenameInitials value="PO"/>
<affiliation>
<display
value="Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor3"/>
<type value="Practitioner"/>
<display value="Guyatt GH"/>
</contributor>
<forenameInitials value="GH"/>
<affiliation>
<display
value="Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor4"/>
<type value="Practitioner"/>
<display value="Schnell O"/>
</contributor>
<forenameInitials value="O"/>
<affiliation>
<display
value="Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor5"/>
<type value="Practitioner"/>
<display value="Rydén L"/>
</contributor>
<forenameInitials value="L"/>
<affiliation>
<display
value="Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor6"/>
<type value="Practitioner"/>
<display value="Marx N"/>
</contributor>
<forenameInitials value="N"/>
<affiliation>
<display
value="Clinic for Cardiology, Angiology, and Intensive Care Medicine, RWTH Aachen University, University Hospital Aachen, Aachen, Germany."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor7"/>
<type value="Practitioner"/>
<display value="Brosius FC"/>
</contributor>
<forenameInitials value="FC"/>
<affiliation>
<display
value="Division of Nephrology, University of Arizona College of Medicine Tucson, Tucson, AZ, USA."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor8"/>
<type value="Practitioner"/>
<display value="Mustafa RA"/>
</contributor>
<forenameInitials value="RA"/>
<affiliation>
<display
value="Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Kansas City, MI, USA."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor9"/>
<type value="Practitioner"/>
<display value="Agarwal A"/>
</contributor>
<forenameInitials value="A"/>
<affiliation>
<display
value="Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."/>
</affiliation>
<affiliation>
<display
value="Department of Medicine, McMaster University, Hamilton, ON, Canada."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor10"/>
<type value="Practitioner"/>
<display value="Zou X"/>
</contributor>
<forenameInitials value="X"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor11"/>
<type value="Practitioner"/>
<display value="Mao Y"/>
</contributor>
<forenameInitials value="Y"/>
<affiliation>
<display
value="Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor12"/>
<type value="Practitioner"/>
<display value="Asadollahifar A"/>
</contributor>
<forenameInitials value="A"/>
<affiliation>
<display
value="Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor13"/>
<type value="Practitioner"/>
<display value="Chowdhury SR"/>
</contributor>
<forenameInitials value="SR"/>
<affiliation>
<display
value="Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor14"/>
<type value="Practitioner"/>
<display value="Zhai C"/>
</contributor>
<forenameInitials value="C"/>
<affiliation>
<display
value="Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor15"/>
<type value="Practitioner"/>
<display value="Gupta S"/>
</contributor>
<forenameInitials value="S"/>
<affiliation>
<display
value="Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor16"/>
<type value="Practitioner"/>
<display value="Gao Y"/>
</contributor>
<forenameInitials value="Y"/>
<affiliation>
<display
value="Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."/>
</affiliation>
<affiliation>
<display
value="Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor17"/>
<type value="Practitioner"/>
<display value="Lima JP"/>
</contributor>
<forenameInitials value="JP"/>
<affiliation>
<display
value="Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor18"/>
<type value="Practitioner"/>
<display value="Numata K"/>
</contributor>
<forenameInitials value="K"/>
<affiliation>
<display
value="Department of Emergency Medicine, St Marianna University School of Medicine, Kawasaki, Japan."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor19"/>
<type value="Practitioner"/>
<display value="Qiao Z"/>
</contributor>
<forenameInitials value="Z"/>
<affiliation>
<display
value="West China School of Medicine, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor20"/>
<type value="Practitioner"/>
<display value="Fan Q"/>
</contributor>
<forenameInitials value="Q"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor21"/>
<type value="Practitioner"/>
<display value="Yang Q"/>
</contributor>
<forenameInitials value="Q"/>
<affiliation>
<display
value="Department of Nephrology, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor22"/>
<type value="Practitioner"/>
<display value="Jin Y"/>
</contributor>
<forenameInitials value="Y"/>
<affiliation>
<display
value="Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor23"/>
<type value="Practitioner"/>
<display value="Ge L"/>
</contributor>
<forenameInitials value="L"/>
<affiliation>
<display
value="Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor24"/>
<type value="Practitioner"/>
<display value="Yang Q"/>
</contributor>
<forenameInitials value="Q"/>
<affiliation>
<display
value="Evidence-Based Nursing Centre, School of Nursing, Lanzhou University, Lanzhou, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor25"/>
<type value="Practitioner"/>
<display value="Zhu H"/>
</contributor>
<forenameInitials value="H"/>
<affiliation>
<display
value="Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor26"/>
<type value="Practitioner"/>
<display value="Yang F"/>
</contributor>
<forenameInitials value="F"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Chengdu Fifth People's Hospital, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor27"/>
<type value="Practitioner"/>
<display value="Chen Z"/>
</contributor>
<forenameInitials value="Z"/>
<affiliation>
<display
value="Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Tianjin, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor28"/>
<type value="Practitioner"/>
<display value="Lu X"/>
</contributor>
<forenameInitials value="X"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor29"/>
<type value="Practitioner"/>
<display value="He S"/>
</contributor>
<forenameInitials value="S"/>
<affiliation>
<display
value="Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor30"/>
<type value="Practitioner"/>
<display value="Chen X"/>
</contributor>
<forenameInitials value="X"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, First People's Hospital of Shuangliu District, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor31"/>
<type value="Practitioner"/>
<display value="Lyu X"/>
</contributor>
<forenameInitials value="X"/>
<affiliation>
<display
value="Department of Radiology, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor32"/>
<type value="Practitioner"/>
<display value="An X"/>
</contributor>
<forenameInitials value="X"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor33"/>
<type value="Practitioner"/>
<display value="Chen Y"/>
</contributor>
<forenameInitials value="Y"/>
<affiliation>
<display
value="Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor34"/>
<type value="Practitioner"/>
<display value="Hao Q"/>
</contributor>
<forenameInitials value="Q"/>
<affiliation>
<display
value="School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor35"/>
<type value="Practitioner"/>
<display value="Standl E"/>
</contributor>
<forenameInitials value="E"/>
<affiliation>
<display
value="Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor36"/>
<type value="Practitioner"/>
<display value="Siemieniuk R"/>
</contributor>
<forenameInitials value="R"/>
<affiliation>
<display
value="Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor37"/>
<type value="Practitioner"/>
<display value="Agoritsas T"/>
</contributor>
<forenameInitials value="T"/>
<affiliation>
<display
value="Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."/>
</affiliation>
<affiliation>
<display
value="Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor38"/>
<type value="Practitioner"/>
<display value="Tian H"/>
</contributor>
<forenameInitials value="H"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor39"/>
<type value="Practitioner"/>
<display value="Li S"/>
</contributor>
<forenameInitials value="S"/>
<affiliation>
<display
value="Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China lisheyu@gmail.com."/>
</affiliation>
</entry>
</contributorship>
</citedArtifact>
</Citation>